NexusPharma is dedicated to the discovery of novel therapeutics that modulate protein-protein interactions. Novel drug candidates will be advanced into clinical development for the treatment of cancer through approaches based on non-cytotoxic mechanisms. Thus, NexusPharma also develops new technologies that aid drug discovery - such as novel cell based screening assays or patient derived tumor models. Please ask us if we could help you in your dicsovery projects with these technologies !

Applying its patented technologies discovered at Fox Chase Cancer Center, NexusPharma has discovered novel small-molecule protein-protein interaction inhibitors (PPII's) for a variety of biological targets. As a co-founder of NexusPharma, Fox Chase Cancer Center supports the development of a physiological, cost-effective platform for pre-clinical compound assessment along with other research activities at NexusPharma scheduled for the coming years.

Home | Contacts | Directions